The novel platinum(IV) complex LA-12 induces p53 and p53/47 responses that differ from the related drug, cisplatin
Jazyk angličtina Země Velká Británie, Anglie Médium print
Typ dokumentu srovnávací studie, časopisecké články, práce podpořená grantem
PubMed
18454047
DOI
10.1097/cad.0b013e3282f7f500
PII: 00001813-200804000-00005
Knihovny.cz E-zdroje
- MeSH
- amantadin analogy a deriváty farmakologie MeSH
- antitumorózní látky farmakologie MeSH
- buněčný cyklus účinky léků MeSH
- chemorezistence MeSH
- cisplatina farmakologie MeSH
- doxorubicin farmakologie MeSH
- lidé MeSH
- nádorové buněčné linie MeSH
- nádorový supresorový protein p53 genetika metabolismus MeSH
- organoplatinové sloučeniny farmakologie MeSH
- posttranslační úpravy proteinů MeSH
- proliferace buněk účinky léků MeSH
- protein - isoformy genetika metabolismus MeSH
- průtoková cytometrie MeSH
- sekvenční analýza hybridizací s uspořádaným souborem oligonukleotidů MeSH
- signální transdukce MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- srovnávací studie MeSH
- Názvy látek
- amantadin MeSH
- antitumorózní látky MeSH
- bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV) MeSH Prohlížeč
- cisplatina MeSH
- doxorubicin MeSH
- nádorový supresorový protein p53 MeSH
- organoplatinové sloučeniny MeSH
- protein - isoformy MeSH
The platinum(II)-based complex cisplatin is one of the most frequently used antitumour agents; however, a high incidence of harmful side effects and the frequent emergence of acquired resistance are the major clinical problems. The novel platinum(IV)-based complex LA-12 exhibits a high efficacy against cancer cell lines, including cisplatin-insensitive cells, but the mechanisms by which LA-12 perturbs cell growth are unclear. We tested the effects of LA-12 on the p53 response and demonstrate that LA-12 induces unique changes in the profile of gene expression compared with cisplatin and doxorubicin. Furthermore, the ability of LA-12 to disrupt cellular proliferation is greatly enhanced by the expression of p53 and p53/47 indicating both p53-dependent and p53-independent effects of LA-12. Exposure of the human cancer cell lines H1299, A2780, BT549 and BT474 to LA-12 alters the expression of p53 and p53/47 in both a time-dependent and dose-dependent manner. Treatment of cells with a low concentration of the drug results in accumulation of p53 and p53/47 concomitant with their posttranslational modification, whereas a high dose results in the disappearance of both the forms of p53. The distinct p53 activation profile of LA-12 compared with cisplatin and doxorubicin provides a molecular explanation for the ability of this drug to treat cisplatin-resistant cells and indicates its potential usefulness as an alternative antitumour agent in first-line therapy or as a second-line therapy in patients with acquired cisplatin resistance.
Citace poskytuje Crossref.org
The new platinum-based anticancer agent LA-12 induces retinol binding protein 4 in vivo